重症筋無力症(Myasthenia Gravis):世界の治験レビュー(2015年上半期版)

GlobalDataが発行した調査報告書(GDHC2579CTIDB)
◆英語タイトル:Myasthenia Gravis Global Clinical Trials Review, H1, 2015
◆商品コード:GDHC2579CTIDB
◆発行会社(リサーチ会社):GlobalData
◆発行日:2015年3月1日
◆ページ数:77
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD2,500 ⇒換算¥265,000見積依頼/購入/質問フォーム
Site License(同一国内共有可)USD5,000 ⇒換算¥530,000見積依頼/購入/質問フォーム
Enterprisewide License(複数国内共有可)USD7,500 ⇒換算¥795,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。GlobalData社の概要及び新刊レポートはこちらでご確認いただけます。

当調査レポートでは、世界における重症筋無力症(Myasthenia Gravis) 治療の臨床試験動向について調査・分析し、アジア太平洋/欧州/北米/中南米の主要国における治験件数、段階(フェーズ)別の治験件数、進捗状況別の治験件数、治験目標の達成状況、有望な薬剤、治験関連の最新ニュース、代表的な企業・大学・研究機関における治験概要、代表的な治験のプロファイルなどのデータをまとめてお届けいたします。

・イントロダクション
  - 重症筋無力症(Myasthenia Gravis)
  - 当レポートの概要
・重症筋無力症(Myasthenia Gravis):各地域別治験状況
  - 各国の治験件数及び平均被験者数
   アジア太平洋の主要国における治験件数
   欧州の主要国における治験件数
   北米の主要国における治験件数
   中東・アフリカの主要国における治験件数
   中南米の主要国における治験件数
・G7諸国での治験件数
・G7諸国での治験件数:段階別
・G7諸国での治験件数:進捗状況別
・段階(フェーズ)別の治験件数:進行中の治験(段階別)
・進捗状況別の治験件数
・治験目標の達成状況
・未完了の治験件数
・一定期間に採用された被験者
・スポンサーの種類別治験件数
・有望なスポンサー
・有望な薬剤
・治験のプロファイル
  - 代表的な企業における治験概要
  - 代表的な大学・研究機関における治験概要
・5つの代表的な治験のプロファイル
【レポートの概要】

Myasthenia Gravis Global Clinical Trials Review, H1, 2015

Summary

GlobalData’s clinical trial report, “Myasthenia Gravis Global Clinical Trials Review, H1, 2015″ provides data on the Myasthenia Gravis clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Myasthenia Gravis. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Myasthenia Gravis. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each
- Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
- Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to buy

- Understand the dynamics of a particular indication in a condensed manner
- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
- Obtain discontinued trial listing for trials across the globe
- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies

【レポートの目次】

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Myasthenia Gravis 6
Report Guidance 6
Clinical Trials by Region 7
Clinical Trials and Average Enrollment by Country 8
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 10
Top Five Countries Contributing to Clinical Trials in Europe 11
Top Countries Contributing to Clinical Trials in North America 12
Top Countries Contributing to Clinical Trials in Middle East and Africa 13
Top Countries Contributing to Clinical Trials in Central and South America 14
Clinical Trials by G7 Countries: Proportion of Myasthenia Gravis to Immunology Clinical Trials 15
Clinical Trials by Phase in G7 Countries 16
Clinical Trials in G7 Countries by Trial Status 17
Clinical Trials by E7 Countries: Proportion of Myasthenia Gravis to Immunology Clinical Trials 18
Clinical Trials by Phase in E7 Countries 19
Clinical Trials in E7 Countries by Trial Status 20
Clinical Trials by Phase 21
In Progress Trials by Phase 22
Clinical Trials by Trial Status 23
Clinical Trials by End Point Status 24
Unaccomplished Trials of Myasthenia Gravis 25
Subjects Recruited Over a Period of Time 26
Clinical Trials by Sponsor Type 27
Prominent Sponsors 28
Top Companies Participating in Myasthenia Gravis Therapeutics Clinical Trials 29
Prominent Drugs 30
Clinical Trial Profiles 31
Clinical Trial Overview of Top Companies 31
F. Hoffmann-La Roche Ltd. 31
Clinical Trial Overview of F. Hoffmann-La Roche Ltd. 31
Cytokinetics, Inc. 32
Clinical Trial Overview of Cytokinetics, Inc. 32
Astellas Pharma Inc. 33
Clinical Trial Overview of Astellas Pharma Inc. 33
Alexion Pharmaceuticals, Inc. 34
Clinical Trial Overview of Alexion Pharmaceuticals, Inc. 34
Volution Immuno Pharmaceuticals (VIP) SA 35
Clinical Trial Overview of Volution Immuno Pharmaceuticals (VIP) SA 35
Grifols, S.A. 36
Clinical Trial Overview of Grifols, S.A. 36
GlaxoSmithKline plc 37
Clinical Trial Overview of GlaxoSmithKline plc 37
Bayhill Therapeutics, Inc. 38
Clinical Trial Overview of Bayhill Therapeutics, Inc. 38
AstraZeneca PLC 39
Clinical Trial Overview of AstraZeneca PLC 39
Amarin Corporation plc 40
Clinical Trial Overview of Amarin Corporation plc 40
Clinical Trial Overview of Top Institutes / Government 41
Sun Yat-sen University 41
Clinical Trial Overview of Sun Yat-sen University 41
University Health Network 42
Clinical Trial Overview of University Health Network 42
Leiden University Medical Center 43
Clinical Trial Overview of Leiden University Medical Center 43
Assistance Publique – Hopitaux de Paris 44
Clinical Trial Overview of Assistance Publique – Hopitaux de Paris 44
Yale University 45
Clinical Trial Overview of Yale University 45
Toronto General Hospital 46
Clinical Trial Overview of Toronto General Hospital 46
FDA Office of Orphan Products Development 47
Clinical Trial Overview of FDA Office of Orphan Products Development 47
The First Affiliated Hospital of Guangzhou University of Traditional Chinese Medicine 48
Clinical Trial Overview of The First Affiliated Hospital of Guangzhou University of Traditional Chinese Medicine 48
Indiana University 49
Clinical Trial Overview of Indiana University 49
Fred Hutchinson Cancer Research Center 50
Clinical Trial Overview of Fred Hutchinson Cancer Research Center 50
Five Key Clinical Profiles 51
Appendix 75
Abbreviations 75
Definitions 75
Research Methodology 76
Secondary Research 76
About GlobalData 77
Contact Us 77
Disclaimer 77
Source 77

List of Tables
Myasthenia Gravis Therapeutics, Global, Clinical Trials by Region, 2015* 7
Myasthenia Gravis Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2015* 8
Myasthenia Gravis Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2015* 9
Myasthenia Gravis Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2015* 10
Myasthenia Gravis Therapeutics Clinical Trials, Europe, Top Five Countries, 2015* 11
Myasthenia Gravis Therapeutics Clinical Trials, North America, Top Countries, 2015* 12
Myasthenia Gravis Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2015* 13
Myasthenia Gravis Therapeutics Clinical Trials, Central and South America, Top Countries, 2015* 14
Proportion of Myasthenia Gravis to Immunology Clinical Trials, G7 Countries (%), 2015* 15
Myasthenia Gravis Therapeutics, G7 Countries, Clinical Trials by Phase, 2015* 16
Myasthenia Gravis Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2015* 17
Proportion of Myasthenia Gravis to Immunology Clinical Trials, E7 Countries (%), 2015* 18
Myasthenia Gravis Therapeutics, E7 Countries, Clinical Trials by Phase, 2015* 19
Myasthenia Gravis Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2015* 20
Myasthenia Gravis Therapeutics, Global, Clinical Trials by Phase, 2015* 21
Myasthenia Gravis Therapeutics, Global, Clinical Trials In Progress by Phase 2015* 22
Myasthenia Gravis Therapeutics, Global, Clinical Trials by Trial Status, 2015* 23
Myasthenia Gravis Therapeutics Clinical Trials, Global, by End Point Status, 2015* 24
Myasthenia Gravis Therapeutics, Global, Terminated Clinical Trials, 2015* 25
Myasthenia Gravis Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2010-2014 26
Myasthenia Gravis Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2015* 27
Myasthenia Gravis Therapeutics Clinical Trials, Global, Key Sponsors, 2015* 28
Myasthenia Gravis Therapeutics Clinical Trials, Global, Top Companies by Phase, 2015* 29
Myasthenia Gravis Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2015* 30
Myasthenia Gravis Therapeutics Clinical Trials Market, Global, Clinical Trials by F. Hoffmann-La Roche Ltd., 2015* 31
Myasthenia Gravis Therapeutics Clinical Trials Market, Global, Clinical Trials by Cytokinetics, Inc., 2015* 32
Myasthenia Gravis Therapeutics Clinical Trials Market, Global, Clinical Trials by Astellas Pharma Inc., 2015* 33
Myasthenia Gravis Therapeutics Clinical Trials Market, Global, Clinical Trials by Alexion Pharmaceuticals, Inc., 2015* 34
Myasthenia Gravis Therapeutics Clinical Trials Market, Global, Clinical Trials by Volution Immuno Pharmaceuticals (VIP) SA, 2015* 35
Myasthenia Gravis Therapeutics Clinical Trials Market, Global, Clinical Trials by Grifols, S.A., 2015* 36
Myasthenia Gravis Therapeutics Clinical Trials Market, Global, Clinical Trials by GlaxoSmithKline plc, 2015* 37
Myasthenia Gravis Therapeutics Clinical Trials Market, Global, Clinical Trials by Bayhill Therapeutics, Inc., 2015* 38
Myasthenia Gravis Therapeutics Clinical Trials Market, Global, Clinical Trials by AstraZeneca PLC, 2015* 39
Myasthenia Gravis Therapeutics Clinical Trials Market, Global, Clinical Trials by Amarin Corporation plc, 2015* 40
Myasthenia Gravis Therapeutics Clinical Trials Market, Global, Clinical Trials by Sun Yat-sen University, 2015* 41
Myasthenia Gravis Therapeutics Clinical Trials Market, Global, Clinical Trials by University Health Network, 2015* 42
Myasthenia Gravis Therapeutics Clinical Trials Market, Global, Clinical Trials by Leiden University Medical Center, 2015* 43
Myasthenia Gravis Therapeutics Clinical Trials Market, Global, Clinical Trials by Assistance Publique - Hopitaux de Paris, 2015* 44
Myasthenia Gravis Therapeutics Clinical Trials Market, Global, Clinical Trials by Yale University, 2015* 45
Myasthenia Gravis Therapeutics Clinical Trials Market, Global, Clinical Trials by Toronto General Hospital, 2015* 46
Myasthenia Gravis Therapeutics Clinical Trials Market, Global, Clinical Trials by FDA Office of Orphan Products Development, 2015* 47
Myasthenia Gravis Therapeutics Clinical Trials Market, Global, Clinical Trials by The First Affiliated Hospital of Guangzhou University of Traditional Chinese Medicine, 2015* 48
Myasthenia Gravis Therapeutics Clinical Trials Market, Global, Clinical Trials by Indiana University, 2015* 49
Myasthenia Gravis Therapeutics Clinical Trials Market, Global, Clinical Trials by Fred Hutchinson Cancer Research Center, 2015* 50

List of Figures
Myasthenia Gravis Therapeutics, Global, Clinical Trials by Region (%), 2015* 7
Myasthenia Gravis Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2015* 8
Myasthenia Gravis Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2015* 9
Myasthenia Gravis Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2015* 10
Myasthenia Gravis Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2015* 11
Myasthenia Gravis Therapeutics Clinical Trials, North America, Top Countries (%), 2015* 12
Myasthenia Gravis Therapeutics Clinical Trials, Middle East and Africa, Top Countries (%), 2015* 13
Myasthenia Gravis Therapeutics Clinical Trials, Central and South America, Top Countries (%), 2015* 14
Proportion of Myasthenia Gravis to Immunology Clinical Trials, G7 Countries (%), 2015* 15
Myasthenia Gravis Therapeutics, G7 Countries, Clinical Trials by Phase, 2015* 16
Myasthenia Gravis Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2015* 17
Proportion of Myasthenia Gravis to Immunology Clinical Trials, E7 Countries (%), 2015* 18
Myasthenia Gravis Therapeutics, E7 Countries, Clinical Trials by Phase, 2015* 19
Myasthenia Gravis Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2015* 20
Myasthenia Gravis Therapeutics, Global, Clinical Trials by Phase (%), 2015* 21
Myasthenia Gravis Therapeutics, Global, Clinical Trials In Progress by Phase, 2015* 22
Myasthenia Gravis Therapeutics, Global, Clinical Trials by Trial Status, 2015* 23
Myasthenia Gravis Therapeutics Clinical Trials, Global, by End Point Status, 2015* 24
Myasthenia Gravis Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2010-2014 26
Myasthenia Gravis Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2015* 27
Myasthenia Gravis Therapeutics Clinical Trials, Global, Key Sponsors, 2015* 28
Myasthenia Gravis Therapeutics Clinical Trials, Global, Top Companies by Phase, 2015* 29
Myasthenia Gravis Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2015* 30
GlobalData Methodology 76

【レポートのキーワード】

重症筋無力症(Myasthenia Gravis)、治験、臨床試験、治験、治療薬

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ 重症筋無力症(Myasthenia Gravis):世界の治験レビュー(2015年上半期版)(Myasthenia Gravis Global Clinical Trials Review, H1, 2015)]についてメールでお問い合わせはこちらでお願いします。


◆H&Iグローバルリサーチのお客様(例)◆